Search Login Register

ipilimumab Summary

Description: an anti-cytotoxic T lymphocyte-associated antigen 4 antibody for treatment of metastatic melanoma and other cancers

Also Known As: MDX 010; MDX-010; MDX-CTLA-4; MDX010

Networked: 771 relevant articles (135 outcomes, 225 trials/studies) for this Bio-Agent

Key Diseases for which ipilimumab is Relevant

  1. Melanoma (Melanoma, Malignant) : 113 outcomes 161 studies in 628 results
  2. Neoplasms (Cancer) : 17 outcomes 38 studies in 201 results
  3. Neoplasm Metastasis (Metastasis) : 11 outcomes 11 studies in 53 results
  4. Prostatic Neoplasms (Prostate Cancer) : 5 outcomes 25 studies in 52 results
  5. Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) : 2 outcomes 6 studies in 14 results
Show All >>

Drugs Related to ipilimumab

  1. cytotoxic T-lymphocyte antigen 4
  2. Antigens
  3. Dacarbazine (DIC)
  4. sipuleucel-T (APC8015)
  5. Antibodies
  6. CP-675,206
  7. Paclitaxel (Taxol)
  8. Carboplatin (JM8)
  9. Interleukin-2 (IL2)
  10. infliximab (Remicade)
Show All >>

Therapies Related to ipilimumab

  1. Immunotherapy
  2. Castration
  3. Radiotherapy
  4. Aftercare (After-Treatment)
  5. Biological Therapy
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.